AngioDynamics, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by AngioDynamics, Inc. on November 19, 2019, covering events occurring on November 18, 2019. The filing addresses executive compensation adjustments related to the interim Chief Financial Officer role.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The only financial figure disclosed is an increase in executive compensation of $15,000 per month.
Material Changes
On November 18, 2019, the Compensation Committee approved an additional $15,000 per month in compensation for Stephen A. Trowbridge, effective November 1, 2019. This increase is in addition to his existing annual base salary and is specific to his service as interim Chief Financial Officer, a role he assumed on October 23, 2019, while continuing as Senior Vice President and General Counsel.
Guidance, Outlook, and Risks
The filing contains no guidance, outlook, management commentary on business performance, risks, contingencies, or unusual items beyond the executive compensation adjustment.
Key Facts for Investor Verification
- Stephen A. Trowbridge serves as both Senior Vice President, General Counsel, and Interim Chief Financial Officer.
- His compensation was increased by $15,000 per month effective November 1, 2019, for his interim CFO duties.
- The interim CFO appointment was originally disclosed in an 8-K filed on October 22, 2019.
- No financial performance data is included in this specific filing.